Can we bridge the induction strength of T-DXd + Pertuzumab (DB09) with the maintenance success of PATINA? Drs. Pegram and Iyengar explore how CDK4/6 inhibition, endocrine therapy, and HER2-targeted induction may converge to reshape metastatic treatment paradigms.
Bridging PATINA and DB09: The Evolving Induction Followed by Maintenance Strategy
You may also like
Recommended Videos
